Logo1
ICCS - 2021 36th Annual Clinical Cytometry Course
Mr pencil

How would you like your name to appear on your certificate?



What activities did you attend at the event?
Agreement
By completing this form, you attest that you have participated in all selected activities in thier entirety.
Please rate the following:
The program was relevant to my work.
Content matched stated objectives.
Usefulness of handouts/AV/technology.
Quality of facilities and facility accommodations.
How well did the educational sessions give a balanced view of therapeutic options, including the use of generic names?
If you rated any of the above questions with 'fair,' 'poor,' 'disagree,' or 'strongly disagree' please explain in detail (e.g. session title, speaker name, situtation):
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
The instructor was knowledgeable about the content
Objective 1: Understand the scientific basis of clinical flow cytometry and its applications in the diagnosis of hematologic disease.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
The instructor presented the subject matter clearly
Objective 2: Become familiar with the latest technical advances in flow cytometry that can be applied in their own laboratories.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
The instructor was responsive to participants
Objective 3: Increase their ability to interpret flow cytometry to improve patient diagnosis and care.
By meeting the above objective my professional competence will increase because I have acquired new strategies to use in my practice.
By meeting the above objective my professional performance will improve because I should be able to implement the new strategies.
By meeting the above objective my patient outcomes should improve due to the implementation of newly-learned strategies.
The teaching methods used were appropriate to the objectives
The instructor used technology effectively
Describe the utility of flow cytometry in the diagnosis of benign and malignant hematolymphoid disorders
Recognize the components of a flow cytometer
Describe an approach to panel design for a flow cytometry assay and what elements should be considered
Discuss the purpose and fundamentals of method validation for flow cytometry assays (both qualitative and quantitative)
Identify recommended data sets for each validation parameter along with statistical examples
The instructor used technology effectively
Define factors that are taken into account to determine validation strategies
Define assay-specific points for validation, including the conversion from an IVD to an LDT
Discuss procedural, quality assurance, and QC issues related to the validation of a CD34+ stem cell enumeration assay and review relevant CAP checklist items
Discuss procedural, quality assurance, and QC issues related to the validation of modifying an existing leukemia/lymphoma panel
Review diagnostic pitfalls in flow cytometry data analysis and strategies for troubleshooting artifacts and potential errors in flow cytometry data
The instructor used technology effectively
Recognize normal myeloid and lymphoid populations and their maturation patterns by flow cytometry
Review normal populations only seen in certain contexts, such as pediatric specific populations
Describe the expression patterns of normal cells in blood, bone marrow, lymph node, and thymus and describe where they fall on forward versus side scatter and on CD45 versus side scatter
The instructor used technology effectively
Identify normal and abnormal B cell populations and discuss the utility of flow cytometry in the classification of B cell lymphomas
Use flow cytometry data to diagnose and classify cases of acute lymphoblastic leukemia and acute myeloid leukemia
recognize unusual phenotypic variants of B cell neoplasms
Recognize complicated patterns of clonal structure and marker gain/loss in high grade B cell lymphoma lesions
Describe pitfalls in the routine diagnosis of acute lymphoblastic leukemia
The instructor used technology effectively
Recognize normal components of bone marrow on bivariate dot plots of flow cytometry data
Use software to analyze fcs files of flow cytometry data to diagnose cases of acute leukemia and lymphoma based on patterns of antigen expression
Distinguish abnormal from normal populations on flow cytometry plots of CD45 vs side scatter
Describe the value of color gating in the analysis of flow cytometry data
The instructor used technology effectively
Describe strategy to identify neoplastic myeloid blasts through a case-based approach
Distinguish acute myeloid leukemia and mixed phenotype acute leukemia including integration of morphologic and genetic findings
Describe the methodological principles of minimal residual disease testing in acute myeloid leukemia and acute lymphoblastic leukemia
Discuss the general strategy for MRD assessment post therapy
Recognize the advantages and limitations of different methods for minimal residual disease testing
The instructor used technology effectively
Identify T and NK cells by flow cytometry and recognize normal antigen expression
Identify aberrant plasma cell populations and use flow cytometry to classify plasma cell neoplasms
Recognize phenotypic aberrancies that can help to identify abnormal T and NK cells by flow cytometry
Describe the characteristic phenotypes associated with T and NK cell lymphomas based on the WHO classification
Please tell us about any sessions you found particularly good or bad.
Please tell us about any objectives you feel we accomplished well or poorly.
Please tell us about any presenters you found particularly good or bad.
Please answer the following:
Do you believe this activity was appropriate for the scope of your professional activities?
Was the educational content scientifically sound?
If faculty spoke about off-label or investigational uses of a product, was that information disclosed to you?
Was the mode of education effective to learning?
If you answered "No" to any of the above questions, please explain.
Did you perceive any product/service/company/commercial bias in any educational session you attended or materials you received?
If you answered "Yes" to the above question, please detail the situation below (e.g. session title, speaker name):
Were you solicited by sales personnel in an educational room (other areas do not matter) while you attended this educational activity?
If you answered "Yes" to the above question, please explain in detail (e.g. who, when, where):
How much did you learn as a result of this education program?
What specifically did you learn during this activity that you intend to integrate into your practice?

What questions have arisen in your practice for which you need answers/strategies that you can implement?

What patient/client problems or patient/client challenges do you feel you are not able to address appropriately or to your satisfaction?
What problems are your patients/clients communicating to you that need attention or follow up?

Are you interested in basic, intermediate or advanced level trainings?

What barriers might you have that would interfere with implementation of new information learned from this training?

How can this training (the overall meeting) be improved to better impact competence, performance and/or patient/client outcomes?

Additional comments:

How did you attend this course?
Mr question
Provided by amedco